| |
Pablo Tebas, M.D.
Dr. Pablo Tebas
directs the adult AIDS Clinical Trials Unit (ACTU) of the University
of Pennsylvania. His main research interests are the treatment of HIV
infection and the study of the metabolic complications associated with
HIV infection and its treatment. The introduction of highly active antiretroviral
therapy (HAART) has resulted in significant reductions in the morbidity
and mortality associated with HIV infection. Unfortunately, the use
of HAART has also been associated with significant adverse effects,
including dyslipidemia and insulin resistance, bone disease and fat
redistribution. Current studies are directed to understand better the
mechanisms of these complications and prevent their development. Current
outpatient and inpatient clinical activities center in the Hospital
of the University of Pennsylvania where he follows general ID and HIV
infected patients.
Selected publications:
Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel, B,
Tebas, P, Raffi, F, Trottier, B, Bellos, N, Saag M, Cooper D. A, Westby M, Tawadrous M, Sullivan J. F, RidgwayC, Dunne M. W, Felstead S, Mayer H, van der Ryst, E. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008;359(14):1442-55.
Tebas P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr 2008 ;49 Suppl 2:S86-92.
Tebas P, Henry WK, Matining R, Weng-Cherng D, Schmitz J, Valdez H, et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS ONE2008;3:e2021.
Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, Shevitz A, Feinberg J, Collier AC, Shikuma C, Brizz B, Sattler F. Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). J Acquir Immune Defic Syndr 2007;45:193-200.
Dube MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, Roubenoff R, Tebas P. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr 2007;45:508-514.
Contact:
Pablo Tebas, M.D.
AIDS Clinical Trial Unit
8 Penn Tower
34th & Civic Center Blvd.
Philadelphia, PA 19104-4283
pablo.tebas@uphs.upenn.edu
(215) 349-8092
Education:
Medical School: Universidad Autonoma de Madrid, Spain
ID Training: Washington University in Saint Louis, Missouri
Academic Rank: Professor of Medicine
|
